Tien Liang BioTech Co (ROCO:4127) Other Current Receivables: NT$1.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4127 Tien Liang BioTech Co Ltd ROCO:4127
37 GF Score
Price NT$84.90
GF Value NT$45.56
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Tien Liang BioTech Co Other Current Receivables?

Tien Liang BioTech Co ROCO:4127 +9.97% 37 Other Current Receivables is NT$1.2 Mil as of Mar. 2026. GuruFocus rates ROCO:4127 with a GF Score™ of 37/100 and a GF Value™ of NT$45.56 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Tien Liang BioTech Co's Other Current Receivables for the quarter that ended in Mar. 2026 was NT$1.2 Mil.

Tien Liang BioTech Co's quarterly Other Current Receivables declined from Sep. 2025 (NT$6.78 Mil) to Dec. 2025 (NT$5.57 Mil) but then stayed the same from Dec. 2025 (NT$5.57 Mil) to Mar. 2026 (NT$1.20 Mil).

Tien Liang BioTech Co's annual Other Current Receivables declined from Dec. 2023 (NT$51.64 Mil) to Dec. 2024 (NT$15.26 Mil) and declined from Dec. 2024 (NT$15.26 Mil) to Dec. 2025 (NT$5.57 Mil).

Tien Liang BioTech Co Other Current Receivables Related Terms

Tien Liang BioTech Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Tien Liang BioTech Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tien Liang BioTech Co Other Current Receivables Chart

Tien Liang BioTech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.87 58.85 51.64 15.26 5.57

Tien Liang BioTech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.75 12.38 6.78 5.57 1.20
ROCO:4127
37GF Score
Tien Liang BioTech Co Ltd ROCO:4127
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tien Liang BioTech Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$1.2 Mil mean?
Tien Liang BioTech Co (ROCO:4127) has a Other Current Receivables of NT$1.2 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Tien Liang BioTech Co and its competitors.
Is Tien Liang BioTech Co's Other Current Receivables too high?
Tien Liang BioTech Co's current Other Current Receivables is NT$1.2 Mil. Overall, Tien Liang BioTech Co has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tien Liang BioTech Co's Other Current Receivables compare to ZTS?
Tien Liang BioTech Co's Other Current Receivables of NT$1.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Tien Liang BioTech Co and its competitors. Tien Liang BioTech Co's current Other Current Receivables is NT$1.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tien Liang BioTech Co stock overvalued right now?
Based on GuruFocus' analysis, Tien Liang BioTech Co (ROCO:4127) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$45.56, compared to a current price of NT$84.90 — trading 86.3% above its estimated fair value. The current Other Current Receivables is NT$1.2 Mil. Tien Liang BioTech Co's overall GF Score™ is 37/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Tien Liang BioTech Co (ROCO:4127), the current Other Current Receivables is NT$1.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tien Liang BioTech Co (ROCO:4127) Overvalued in 2026?

Based on GuruFocus' analysis, Tien Liang BioTech Co stock appears to be overvalued. The current stock price of NT$84.90 is trading 86.3% above its estimated GF Value™ of NT$45.56. GuruFocus considers Tien Liang BioTech Co to be Significantly Overvalued.

Key valuation signals for ROCO:4127:

  • Other Current Receivables: NT$1.2 Mil
  • GF Value™: NT$45.56 vs. price of NT$84.90 (86.3% above fair value)
  • GF Score™: 37/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tien Liang BioTech Co Business Description

Address No. 147, Section 1, Datong Road, 9th Floor, Xizhi District, New Taipei City, TWN
Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical, and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis, and hepatic diseases.
37GF Score

Get the complete analysis for ROCO:4127

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$84.90
Price
NT$45.56
GF Value